STAT Event: Bispecifics: the next weapon against cancer Jill O'Donnell-Tormey, CEO and Director of Scientific Affairs, chats with STAT about the lifesaving potential of bispecific antibodies. A new type of antibody that can attach to more than one protein target may change the way cancer is treated. Take a look at some of the entrants in a hot new field. Speakers: Irene Ghobrial, MD, Lavine Family Chair of Preventative Cancer Therapy, Professor of Medicine, Dana Farber Cancer Institute Jill O’Donnell-Tormey, PhD, CEO and Director of Scientific Affairs, Cancer Research Institute Damian Garde, National Biotech Reporter, STAT (moderator) Tony Polverino, PhD, Executive Vice President, Early Development and Chief Scientific Officer, Zymeworks (sponsor speaker) Read more: Post navigation Giving Tuesday 2020 Read Story Answer to Cancer x Peloton Ride Read Story